Log in with your email address username.


[Correspondence] Low-dose hydrocortisone in extremely preterm infants

We read with interest the results of the PREMILOC trial (April 30, p 1827)1 and would like to underline some shortcomings. The authors are to be highly congratulated because this is the largest randomised controlled trial (RCT) concluding that early, low-dose hydrocortisone significantly improves the rate of survival without bronchopulmonary dysplasia in extremely preterm infants. Previous RCTs2,3 did not achieve sufficient statistical power or were discontinued because of spontaneous gastrointestinal perforation.